20:45 , May 24, 2019 |  BioCentury  |  Finance

Europe: Some spots hotter than others

There are clear pockets of excellence in Europe, and the U.K. is surging ahead in converting its academic discoveries into company foundations, accounting for 35% of the new companies formed from 2012-18. BioCentury’s analysis of...
23:44 , May 23, 2019 |  BC Extra  |  Company News

May 23 Company Quick Takes: Chiesi gains Raxone rights; plus WuXi Vaccines, a Zika first and more

Chiesi gains rights to Santhera's Raxone for LHON  Santhera Pharmaceuticals Holding AG (SIX:SANN) granted Chiesi Farmaceutici S.p.A. (Parma, Italy) exclusive, worldwide rights outside of the U.S. and Canada to Raxone idebenone for Leber hereditary optic...
23:18 , May 22, 2019 |  BC Extra  |  Politics & Policy

Launch of germline gene editing commission provides first look at priorities, representatives

An international commission tasked with creating a framework for assessing potential clinical applications of human germline genome editing launched Wednesday, providing the first details of the composition of its membership and oversight board, timeline and...
15:32 , May 21, 2019 |  BC Extra  |  Company News

Merck bets on HIF2As with Peloton takeout ahead of planned listing

Days before Peloton was to price an IPO that would fund Phase III testing of its HIF2A program to treat kidney cancer, the biotech has elected instead to take a buyout offer from Merck &...
14:21 , May 20, 2019 |  BC Innovations  |  Distillery Therapeutics

WWP1 inhibitor for MYC-driven prostate cancer

DISEASE CATEGORY: Cancer INDICATION: Prostate cancer In vitro and mouse studies identified a WWP1 inhibitor that could help treat MYC-driven prostate cancer. In a mouse model of MYC-overexpressing prostate cancer, systemic knockout of WWP1 or...
00:17 , May 18, 2019 |  BioCentury  |  Politics, Policy & Law

Cutting through the noise: the handful of pricing proposals the Trump administration or Congress may enact

Scores of proposals for reducing the cost of drugs are swirling around Congress, the White House and the U.S. Department of Health and Human Services, but only a few merit attention outside the beltway. Eliminating...
19:17 , May 15, 2019 |  BC Innovations  |  Translation in Brief

Optimizing base editors to reduce RNA edits

Two Beam co-founders, Keith Joung and David Liu, have separately optimized CRISPR-guided base editors to reduce off-target RNA editing, which, along with unwanted DNA edits, is an emerging problem for the gene engineering tools. Beam...
14:20 , May 14, 2019 |  BC Innovations  |  Distillery Therapeutics

GSK3A inhibition restores asparaginase sensitivity in resistant ALL, AML

DISEASE CATEGORY: Cancer INDICATION: Acute lymphoblastic leukemia (ALL); acute myelogenous leukemia (AML) Cell culture and mouse studies suggest inhibiting GSK3A could help treat asparaginase-resistant T cell and B cell ALL and AML. In a T...
14:19 , May 14, 2019 |  BC Innovations  |  Distillery Techniques

A mouse model to screen therapies for Williams syndrome

TECHNIQUES CATEGORY: Disease models TECHNOLOGY: Transgenics and knockouts GTF2I-deficient mice could be used to screen therapies for Williams syndrome, which is caused by gene deletions on chromosome 7 that lead to learning and cardiovascular problems....
23:04 , May 8, 2019 |  BC Extra  |  Preclinical News

May 8 Preclinical Quick Takes: Moderna, WntRx, schizophrenia, heart attack

Moderna debuts candidate for rare glycogen storage disease  Moderna Inc. (NASDAQ:MRNA) revealed a new preclinical mRNA candidate to treat glycogen storage disease type Ia -- mRNA-3745, which encodes G6PC. The company presented data at the...